Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.
September
30
2020

MS, Rethinking Tomorrow

30 September 2020, 5-6pm | ONLINE event
Merck in collaboration with UCLPartners invites you to this webinar for Academic Health Science Networks (AHSNs) and the MS clinical community

THE ROLE OF AAC-DESIGNATED CLADRIBINE ORAL TABLETS IN RE-ESTABLISHING MS SERVICES AFTER COVID-19

In this promotional webinar we will explore the challenges in getting patients back on to DMT treatment during the COVID-19 pandemic and look at the role of cladribine tablets in appropriate patients to support continuation of MS services during the UK’s COVID-19 response. Each panelist will deliver a short presentation, followed by a facilitated Q&A on the issues discussed.

SPEAKERS


INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – LONDON PERSPECTIVE
Dr Heather Wilson, Consultant Neurologist, National Hospital for Neurology and Neurosurgery, London

INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – NOTTINGHAM UNIVERSITY HOSPITAL PERSPECTIVE
Dr Nikos Evangelou, Consultant Neurologist & Associate Clinical Professor, Nottingham University Hospital

INSIGHTS AND PERSPECTIVES ON CLADRIBINE TABLETS PRE- AND DURING COVID-19 – SOUTH WEST PERSPECTIVE
Professor Jeremy Hobart, Consultant Neurologist, Plymouth Hospitals NHS Trust

CHAIRED BY DR CHARLIE DAVIE, CONSULTANT NEUROLOGIST, UCLPARTNERS

This standalone promotional webinar is aimed at individuals within AHSNs who have an interest in MS services and the MS clinical community, including MS neurologists, MS nurses and pharmacists.

Sign up for this event